Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application
Autor: | Günter Schöllnhammer, M. Langer, A. Hillert, Uwe Barlage, Walther Seiler, Hermann Wetzel, Christoph Hiemke |
---|---|
Rok vydání: | 1994 |
Předmět: |
Adult
Male Metabolite Administration Oral Biological Availability Pharmacology High-performance liquid chromatography Benperidol chemistry.chemical_compound Pharmacokinetics Oral administration medicine Humans Distribution (pharmacology) Cross-Over Studies Chemistry Middle Aged Bioavailability Injections Intravenous Schizophrenia Female Geometric mean Oxidation-Reduction Half-Life medicine.drug |
Zdroj: | Psychopharmacology. 116:457-463 |
ISSN: | 1432-2072 0033-3158 |
DOI: | 10.1007/bf02247478 |
Popis: | Pharmacokinetics and bioavailability of benperidol were determined in 13 schizophrenic patients after acute administration of 6 mg benperidol as an intravenous (i.v.) bolus injection, orally as liquid, and orally as tablets using a partially randomized cross-over design. Drug plasma levels were determined by high performance liquid chromatography with electrochemical detection and subjected to model independent pharmacokinetic analyses. After i.v. dosing the geometric means (mean-g) were 3.2 min for the distribution half-life, 5.80 h for the elimination half-life (t1/2 beta), 4.21 l/kg for the distribution volume, 7.50 h for the mean residence time (MRT), and 0.50 l/(h*kg) for the clearance. After oral administration as liquid and as tablet mean-g data for the time lag until the first appearance of measurable plasma concentrations were 0.33 and 1.1 h, mean-g t1/2 beta values were 5.5 and 4.7 h, respectively, mean-g tmax data were 1.0 h and 2.7 h, mean-g MRT values were 8.44 and 8.84 h, and mean-g Cmax maxvalues were 10.2 and 7.3 ng/ml. Differences between liquid and tablet administration were statistically significant for time lag, tmax, and Cmax. Mean-g absolute bioavailabilities were computed as 48.6% after liquid and 40.2% after tablet administration respectively. All parameters studied exhibited large intersubject variation. The plasma concentrations of the presumed metabolite "reduced benperidol" were found to be very low. |
Databáze: | OpenAIRE |
Externí odkaz: |